Cargando…
Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
PURPOSE: To evaluate the short-term effects of intravitreal faricimab (IVF) in treatment-resistant neovascular age-related macular degeneration (nAMD) subjects previously treated with intravitreal aflibercept (IVA). METHODS: A retrospective review was conducted on nAMD patients undergoing IVA therap...
Autores principales: | Rush, Ryan B, Rush, Sloan W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747838/ https://www.ncbi.nlm.nih.gov/pubmed/36532820 http://dx.doi.org/10.2147/OPTH.S395279 |
Ejemplares similares
-
One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B
Publicado: (2023) -
One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema
por: Rush, Ryan B
Publicado: (2023) -
Faricimab for Treatment-Resistant Diabetic Macular Edema
por: Rush, Ryan B, et al.
Publicado: (2022) -
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022) -
Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration
por: Kishi, Maya, et al.
Publicado: (2023)